The purpose of this study was to evaluate the clinical significance of single nucleotide polymorphisms in TLR1, TLR2, TLR6, and TAK1 in patients with metastatic colorectal cancer (mCRC). We genotyped 9 SNPs of TLR1, TLR2, TLR6, and TAK1 in mCRC patients treated with 1st-line FOLFIRI (combination therapy of irinotecan, 5-fluorouracil and folinic acid) plus bevacizumab, using a discovery cohort (TRIBE trial, n=228) and a validation cohort (FIRE-3 trial, n=297), and analyzed for the association with response rate (RR), progression-free survival (PFS), and overall survival (OS). There was a significant association of TLR1 rs5743618 (T1805G) with the clinical outcome. In the TRIBE cohort, a homozygous wild-type genotype (T/T), associated with a significantly lower RR compared to variant T/G and G/G genotypes (43% vs. 62%, P=0.025), and this observation was validated in the FIRE-3 cohort (46% vs. 65%, P=0.021). In addition, those patients with the T/T genotype had significantly worse PFS (median: 8.2 vs. 10.5 months, HR: 1.57, 95%CI: 1.09–2.28, P=0.014) and OS (median: 19.9 vs. 27.9 months, HR: 1.63, 95%CI: 1.14–2.35, P=0.007), compared to those with other genotypes in the TRIBE cohort. These differences remained statistically significant in multivariate analysis. Our data suggest that TLR1 rs5743618 could serve as a predictor of clinical response to FOLFIRI plus bevacizumab in mCRC patients.